July 2024 in “Journal of Investigative Dermatology” ITK inhibitors may effectively treat alopecia areata.
November 2025 in “Journal of Investigative Dermatology” TEC kinases may help cause inflammation in vitiligo and could be targeted for treatment.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
4 citations
,
November 2023 in “Frontiers in immunology” New treatments targeting T-cell pathways are needed for better alopecia areata management.
9 citations
,
May 2023 in “Inflammation Research” New small molecule drugs show promise in treating complex skin diseases but need more safety research.
January 2026 in “Frontiers in Molecular Biosciences” A new method helps diagnose alopecia areata using specific gene markers and could guide targeted treatments.
84 citations
,
August 2023 in “Drugs” Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.
January 2021 in “Journal of Cancer Therapy” Tyrosine Kinase Inhibitors are effective against cancer but can cause skin, digestive, and blood side effects, including hair loss.
Ritlecitinib helps reduce inflammation and promote hair regrowth in alopecia areata, especially in patchy-type cases.
49 citations
,
February 2022 in “Drug Design Development and Therapy” Ritlecitinib shows promise for hair regrowth in alopecia areata patients.
11 citations
,
September 2024 in “Journal of the European Academy of Dermatology and Venereology” Hair regrows faster in alopecia areata than skin re-pigments in vitiligo due to differences in stem cells and treatment effects.
3 citations
,
September 2025 in “Frontiers in Immunology” JAK inhibitors are effective for treating moderate-to-severe alopecia areata.
December 2025 in “Actas Dermo-Sifiliográficas” Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.
4 citations
,
March 2025 in “The Journal of Dermatology” Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.
September 2024 in “Drugs & Therapy Perspectives” Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.
25 citations
,
September 2020 in “Molecules” Quercitrin may help treat hair loss by promoting hair growth and improving cell health.
176 citations
,
August 2015 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Alopecia areata involves immune activation in the scalp, suggesting treatments targeting TH1, TH2, and IL-23 pathways.
42 citations
,
September 2017 in “Advances in protein chemistry and structural biology” Surface Plasmon Resonance is a useful tool for studying protein interactions and has potential for future technological advancements.
40 citations
,
March 2019 in “Nature Communications” CRAC channels are crucial for the development and function of specialized immune cells, preventing severe inflammation and autoimmune diseases.
6 citations
,
June 2024 in “Scientific Reports” RoPod helps study plant root cell changes and autophagy with minimal stress.
1 citations
,
January 2021 CD4+ skin cells may be precursors to basal cell carcinoma.
70 citations
,
December 2004 in “Differentiation” The study identified and characterized new keratin genes linked to hair follicles and epithelial tissues.
46 citations
,
December 2001 in “Journal of Endocrinology/Journal of endocrinology” FLRG and follistatin have different roles in wound healing.
4 citations
,
July 2024 in “Pharmacology Research & Perspectives” Ritlecitinib is safe and may effectively treat alopecia areata.
1 citations
,
January 2025 in “CPT Pharmacometrics & Systems Pharmacology” Ritlecitinib effectively regrows eyebrow and eyelash hair in alopecia areata, with 50 mg being the best dose.
8 citations
,
October 2021 in “Microbiology spectrum” Researchers identified five new potential targets for leishmaniasis treatment, suggesting repurposing existing drugs could be effective.
34 citations
,
August 2019 in “Journal of Allergy and Clinical Immunology” mTORC2 is crucial for healthy skin barrier by regulating lipids and filaggrin.
6 citations
,
January 2023 in “International journal of molecular sciences” Mast cells and CD8 T cells interact closely in skin diseases, affecting each other's behavior and contributing to conditions like psoriasis and eczema.
December 2022 in “Dermatology and Therapy” Alopecia areata needs more recognition and better treatment access in Latin America to improve patient care and outcomes.
9 citations
,
April 2021 in “Frontiers in Immunology” Unconventional lymphocytes are important for quick immune responses and healing of skin and mucosal barriers.